Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
|Articles|February 3, 2003
New drops first to treat cause and symptoms of dry eye
Patients with keratoconjunctivitis sicca (or dry eye) now have a therapeutic option that both relieves symptoms and treats the underlying disease. The FDA recently approved cyclosporine (Restasis, Allergan) 0.5% ophthalmic emulsion to increase tear production in patients whose tear production is believed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. The company expects to launch Restasis in early April.
Advertisement
Advertisement
Related to this article
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.
In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.
Advertisement
Advertisement
Trending on Drug Topics
1
Nicotine Pouches Create Opportunity for Pharmacist Counseling
2
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
3
FDA Approves Finerenone for Chronic Kidney Disease With Type 1 Diabetes
4
Worth a Shot: How ACIP Changes Might Impact Vaccine Access, Coverage
5